Harbin Pharmaceutical Group Co., Ltd. Harbin Pharmaceutical Group has two national-level enterprise technology centers, a postdoctoral research workstation, a provincial-level pharmaceutical preparation engineering technology research center, and a provincial-level antibiotic engineering technology research center. There are 566 people with professional titles, senior engineers and people receiving government subsidies***. Harbin Pharmaceutical Group has created a scientific research and development system of "one center and five sub-centers". Harbin Pharmaceutical Group Technology Center (Bioengineering Research Center); Anti-infective Drug Research Center; Modern Traditional Chinese Medicine Research Center; Pharmaceutical Preparation Research Center; OTC Drugs and Health Care Food Research Center; Animal Vaccine and Veterinary Drug Research Center. Harbin Pharmaceutical Group has carried out multi-faceted cooperation on 25 projects with 23 scientific research units in colleges and universities, including Tsinghua University, Chinese Academy of Sciences, China Pharmaceutical University, and Shenyang Pharmaceutical University.
The Heilongjiang Provincial Biological Products Factory, a subsidiary of Harbin Pharmaceutical Group, cooperated with the Heilongjiang Provincial Veterinary Research Institute to establish a research center in the factory; at the end of 2003, Harbin Pharmaceutical Group and Harbin Medical University (Heilongjiang Provincial Biomedical Engineering Key Laboratory) first established the Harbin Pharmaceutical Group Biomedical Engineering R&D Center; the Heilongjiang Provincial Biological Products Factory, a subsidiary of the Harbin Pharmaceutical Group, established a strategic alliance and collaboration with the Harbin Veterinary Research Institute of the Chinese Academy of Agricultural Sciences, and successfully introduced the world's first Avian influenza vaccine production technology; the Drug Preparation Center and Dr. *** who returned from the United States have jointly established a solid and liquid sustained-release controlled-release targeted drug delivery platform. In 2006, they introduced excellent postdoctoral fellows in lipid emulsion and are currently developing intravenous emulsions. research. Pay attention to talent introduction and training. In order to build a highland for scientific research talents of the group, we have successively completed the establishment of a platform for high-level innovative talent training such as biomedicine with Harbin Medical University and Northeast Forestry University, and a platform for modern traditional Chinese medicine with the University of Traditional Chinese Medicine. At the same time, we have made full use of the postdoctoral workstation to provide backup for the company in a planned manner. Talent cultivation. At present, Harbin Pharmaceutical Group has more than 100 scientific and technical personnel studying for doctoral and master's degrees, providing a strong talent reserve for the future development of Harbin Pharmaceutical Group. The group company's scientific and technological capabilities have gradually increased, and it has undertaken 36 national, provincial and municipal scientific research projects, including two national "863" projects; in 2005, it also undertook the national "Tenth Five-Year Plan" major scientific and technological project 'Innovative Drugs and Modernization of Traditional Chinese Medicine' Special project (Research on Acanthopanax for Injection); National Technology Center Innovation Capacity Building Project (Special Topic on "Recombinant Protein Technology R&D and Innovation Capabilities Expressed by Eukaryotic Cells") and State Intellectual Property Office Special Research (Antibiotic Patent Strategy Research) and other national-level scientific research subject. From 2001 to 2005, more than 100 new product approvals were obtained, of which 20 were national class III or above new drugs. As of the first half of 2006, the group company has more than 150 new products awaiting approval or under development.
There are 6 national first-class new drugs, three of which are undergoing clinical trials and are expected to obtain production approval before 2008. The traditional Chinese medicine powder for injection is the first traditional Chinese medicine dosage form in China, and its product technology is world-leading. The group company took the lead in mastering the production technology of antibiotic raw materials in China. Through continuous technical research and application of new technologies, the main technical indicators have been greatly improved. By promoting new strains of penicillin and adopting new technologies such as membrane filtration and "three-in-one", the yield of penicillin has been greatly improved, and the technical indicators have always maintained the leading level in the country. The production technology level of cefazolin sodium and amoxicillin sodium is at the internationally advanced level, and the production technology indicators are in the leading position in the country. Chemical preparations have completed the transformation from the first generation: traditional tablets, capsules, injections, etc., to the second generation: sustained-release preparations, enteric-coated preparations, etc. for the purpose of controlling the release rate. At present, the group company has started the third generation of research on controlled-release preparations and targeted drug delivery preparations prepared using biological carrier technologies such as monoclonal antibodies, liposomes, and microspheres, and has achieved certain results. The group company has successfully developed more than 20 new formulation technology varieties: enteric-coated formulations, sustained-release formulations and targeted formulations.